Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
P. A. Cohen
Research Funding - VentiRx
D. W. Northfelt
Research Funding - VentiRx
G. J. Weiss
Research Funding - VentiRx
D. D. Von Hoff
Research Funding - VentiRx
K. Manjarrez
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
G. Dietsch
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
R. M. Hershberg
Employment or Leadership Position - VentiRx
Stock Ownership - VentiRx
R. K. Ramanathan
Research Funding - VentiRx